- Home
- MPB vs KALV Comparison
MPB vs KALV Comparison
Compare MPB & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- KALV
- Stock Information
- Founded
- MPB 1868
- KALV N/A
- Country
- MPB United States
- KALV United States
- Employees
- MPB N/A
- KALV N/A
- Industry
- MPB Major Banks
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- MPB Finance
- KALV Health Care
- Exchange
- MPB Nasdaq
- KALV Nasdaq
- Market Cap
- MPB 691.1M
- KALV 796.4M
- IPO Year
- MPB N/A
- KALV N/A
- Fundamental
- Price
- MPB $30.33
- KALV $13.62
- Analyst Decision
- MPB Buy
- KALV Strong Buy
- Analyst Count
- MPB 2
- KALV 8
- Target Price
- MPB $34.50
- KALV $26.43
- AVG Volume (30 Days)
- MPB 80.9K
- KALV 986.2K
- Earning Date
- MPB 10-22-2025
- KALV 09-11-2025
- Dividend Yield
- MPB 2.66%
- KALV N/A
- EPS Growth
- MPB N/A
- KALV N/A
- EPS
- MPB 2.30
- KALV N/A
- Revenue
- MPB $191,454,000.00
- KALV $1,426,000.00
- Revenue This Year
- MPB $24.57
- KALV N/A
- Revenue Next Year
- MPB $12.23
- KALV $221.95
- P/E Ratio
- MPB $13.06
- KALV N/A
- Revenue Growth
- MPB 13.34
- KALV N/A
- 52 Week Low
- MPB $22.50
- KALV $7.30
- 52 Week High
- MPB $33.87
- KALV $17.28
- Technical
- Relative Strength Index (RSI)
- MPB 63.51
- KALV 45.29
- Support Level
- MPB $29.92
- KALV $13.26
- Resistance Level
- MPB $30.44
- KALV $17.28
- Average True Range (ATR)
- MPB 0.56
- KALV 1.00
- MACD
- MPB -0.03
- KALV -0.02
- Stochastic Oscillator
- MPB 84.91
- KALV 16.44
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.